The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...
A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...
Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply constraints ...
Joshua Cohen is a Boston-based writer who covers health policy. Patients on the weight-loss drug Zepbound regained weight almost one year after stopping treatment, according to a study published ...
Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...
(Zepbound is one of the medication's brand names.) Men, meanwhile, lost 19 percent of their body weight. This is a big move in the weight loss space. Here’s what you need to know about Zepbound.
Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. See ...
Extreme hunger is common after people stop taking GLP-1 drugs like Ozempic and Wegovy, but health experts say these simple ...
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...